{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:41:15Z","timestamp":1792633275547,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"DOI":"10.1007\/s11523-026-01261-w","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:33:03Z","timestamp":1792632783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Olaparib Efficacy Following CDK4\/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8868-988X","authenticated-orcid":false,"given":"Zeynep S\u0131la","family":"G\u00f6kdere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha Koray","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130rem","family":"Bilgetekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naziyet K\u00f6se","family":"Baytemur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Seyyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melike","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercan","family":"G\u00fcm\u00fc\u015fburun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seval","family":"Akay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damla","family":"G\u00fcnen\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011fla","family":"Karao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar Ezgi","family":"Dama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece \u015eahin","family":"Haf\u0131zo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Menek\u015fe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkan","family":"Karadurmu\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"\u00d6z\u00fcdo\u011fru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galip Can","family":"Uyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6rkem","family":"Turhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahad\u0131r","family":"K\u00f6yl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferit","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Nuransoy","family":"Cengiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Kaan","family":"G\u00fcren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"B\u00fct\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cevher Burcu","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131","family":"Ge\u00e7gel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015e\u00fcheda Ata\u015f","family":"\u0130pek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Asarkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bedriye A\u00e7\u0131kg\u00f6z","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"\u00dcnl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekin Aky\u0131ld\u0131z","family":"Usta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"Kanmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"Esin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"Erdemo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atilla","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa Bar\u0131\u015f","family":"Aykan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fclay","family":"Ku\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u015eahbazlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdem","family":"\u00c7ubuk\u00e7u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin Salih","family":"Semiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Sel\u00e7ukbiricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mevl\u00fcde","family":"\u0130nan\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Sar\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Karabulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Odaba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertu\u011frul","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze G\u00f6k\u00f6z","family":"Do\u011fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep G\u00fcls\u00fcm","family":"G\u00fc\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulus Ali","family":"\u015eanl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"\u00c7akar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"G\u00f6kmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna \u00c7akmak","family":"\u00d6ks\u00fczo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devrim","family":"\u00c7abuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan \u00c7a\u011fr\u0131","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"1261_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1261_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2026.103161","volume":"147","author":"\u00c1G Zotano","year":"2026","unstructured":"Zotano \u00c1G, Allweis TM, Foerster R, Palmieri C, Gluz O, Chia S, et al. The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: impact on systemic and surgical treatment decisions. Cancer Treat Rev. 2026;147:103161. https:\/\/doi.org\/10.1016\/j.ctrv.2026.103161.","journal-title":"Cancer Treat Rev"},{"key":"1261_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag183","volume":"31","author":"A Dy","year":"2026","unstructured":"Dy A, Lennerz JK. Ki-67 as a treatment decision modifier in breast cancer. Oncologist. 2026;31:oyag183. https:\/\/doi.org\/10.1093\/oncolo\/oyag183.","journal-title":"Oncologist"},{"key":"1261_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/747318","volume":"2013","author":"P Apostolou","year":"2013","unstructured":"Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. BioMed Res Int. 2013;2013:747318. https:\/\/doi.org\/10.1155\/2013\/747318.","journal-title":"BioMed Res Int"},{"key":"1261_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/jnci\/djaa023","volume":"112","author":"C Hu","year":"2020","unstructured":"Hu C, Polley EC, Yadav S, Lilyquist J, Shimelis H, Na J, et al. The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. J Natl Cancer Inst. 2020;112:1231\u201341. https:\/\/doi.org\/10.1093\/jnci\/djaa023.","journal-title":"J Natl Cancer Inst"},{"key":"1261_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/CLEP.S206949","volume":"11","author":"N Armstrong","year":"2019","unstructured":"Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543\u201361. https:\/\/doi.org\/10.2147\/CLEP.S206949.","journal-title":"Clin Epidemiol"},{"key":"1261_CR7","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"key":"1261_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104634","volume":"208","author":"R Torrisi","year":"2025","unstructured":"Torrisi R, Gerosa R, Miggiano C, Saltalamacchia G, Benvenuti C, Santoro A. Beyond failure of endocrine-based therapies in HR+\/HER2 negative advanced breast cancer: what before chemotherapy? A glimpse into the future. Crit Rev Oncol Hematol. 2025;208:104634. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104634.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1261_CR9","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","journal-title":"N Engl J Med"},{"key":"1261_CR10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40487-021-00162-4","volume":"9","author":"JM Collins","year":"2021","unstructured":"Collins JM, Nordstrom BL, McLaurin KK, Dalvi TB, McCutcheon SC, Bennett JC, et al. A real-world evidence study of CDK4\/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status. Oncol Ther. 2021;9:575\u201389. https:\/\/doi.org\/10.1007\/s40487-021-00162-4.","journal-title":"Oncol Ther"},{"key":"1261_CR11","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010.","journal-title":"Ann Oncol"},{"key":"1261_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","journal-title":"N Engl J Med"},{"key":"1261_CR13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1802905.","journal-title":"N Engl J Med"},{"key":"1261_CR14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ijc.34525","volume":"153","author":"E Senkus","year":"2023","unstructured":"Senkus E, Delaloge S, Domchek SM, Conte P, Im S-A, Xu B, et al. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial. Int J Cancer. 2023;153:803\u201314. https:\/\/doi.org\/10.1002\/ijc.34525.","journal-title":"Int J Cancer"},{"key":"1261_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P, Im S-A, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558\u201366. https:\/\/doi.org\/10.1093\/annonc\/mdz012.","journal-title":"Ann Oncol"},{"key":"1261_CR16","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee K-H, Gon\u00e7alves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31:1526\u201335. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2098.","journal-title":"Ann Oncol"},{"key":"1261_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.breast.2022.10.014","volume":"66","author":"F Miglietta","year":"2022","unstructured":"Miglietta F, Cinquini M, Dieci MV, Cortesi L, Criscitiello C, Montemurro F, et al. PARP-inhibitors for BRCA1\/2-related advanced HER2-negative breast cancer: a meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. Breast. 2022;66:293\u2013304. https:\/\/doi.org\/10.1016\/j.breast.2022.10.014.","journal-title":"Breast"},{"key":"1261_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2026.104715","volume":"86","author":"S Pannunzio","year":"2026","unstructured":"Pannunzio S, Mastrantoni L, Maliziola N, Pontolillo L, Garufi G, Di Monte E, et al. Predicting progression-free survival in hormone-receptor positive (HR+\/HER2\u2212) metastatic breast cancer (MBC) treated with CDK4\/6 inhibitors: a machine learning approach. Breast. 2026;86:104715. https:\/\/doi.org\/10.1016\/j.breast.2026.104715.","journal-title":"Breast"},{"key":"1261_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104148","volume":"192","author":"G Antonarelli","year":"2023","unstructured":"Antonarelli G, Taurelli Salimbeni B, Marra A, Esposito A, Locatelli MA, Trapani D, et al. The CDK4\/6 inhibitors biomarker landscape: the most relevant biomarkers of response or resistance for further research and potential clinical utility. Crit Rev Oncol Hematol. 2023;192:104148. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104148.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1261_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030599","volume":"14","author":"L Collet","year":"2022","unstructured":"Collet L, P\u00e9ron J, Penault-Llorca F, Pujol P, Lopez J, Freyer G, et al. PARP inhibitors: a major therapeutic option in endocrine-receptor positive breast cancers. Cancers. 2022;14:599. https:\/\/doi.org\/10.3390\/cancers14030599.","journal-title":"Cancers"},{"key":"1261_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104544","volume":"83","author":"M Bottosso","year":"2025","unstructured":"Bottosso M, Zurlo C, Miglietta F, Cattelan AC, Iannaccone D, Dieci MV, et al. Impact of germline BRCA1\/2 status on outcomes for patients with HR+\/HER2\u2212 metastatic breast cancer treated with CDK4\/6 inhibitors: a systematic review and meta-analysis. Breast. 2025;83:104544. https:\/\/doi.org\/10.1016\/j.breast.2025.104544.","journal-title":"Breast"},{"key":"1261_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2026.104739","volume":"86","author":"T Guinel","year":"2026","unstructured":"Guinel T, Lusque A, Mailliez A, Massard V, Jacot W, Guiu S, et al. BRCA1\/2, PALB2 mutations and first-line CDK4\/6 inhibitor efficacy in HR+ metastatic breast cancer. Breast. 2026;86:104739. https:\/\/doi.org\/10.1016\/j.breast.2026.104739.","journal-title":"Breast"},{"key":"1261_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00859-z","volume":"11","author":"E Zattarin","year":"2025","unstructured":"Zattarin E, Marra A, Palazzo A, Griguolo G, Vernieri C, Etessami J, et al. Real-world effectiveness of PARP inhibitors after CDK4\/6 inhibitor therapy in BRCA-mutated HR-positive\/HER2-negative advanced breast cancer. NPJ Breast Cancer. 2025;11:145. https:\/\/doi.org\/10.1038\/s41523-025-00859-z.","journal-title":"NPJ Breast Cancer"},{"key":"1261_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-023-07165-x","volume":"204","author":"J Balma\u00f1a","year":"2024","unstructured":"Balma\u00f1a J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O\u2019Shaughnessy J, et al. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast Cancer Res Treat. 2024;204:237\u201348. https:\/\/doi.org\/10.1007\/s10549-023-07165-x.","journal-title":"Breast Cancer Res Treat"},{"key":"1261_CR25","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/j.clbc.2024.10.006","volume":"25","author":"N Jahan","year":"2025","unstructured":"Jahan N, Taraba J, Boddicker NJ, Giridhar KV, Leon-Ferre RA, Tevaarwerk AJ, et al. Real-world evidence on prescribing patterns and clinical outcomes of metastatic breast cancer patients treated with PARP inhibitors: the Mayo Clinic experience. Clin Breast Cancer. 2025;25:e211-e219.e2. https:\/\/doi.org\/10.1016\/j.clbc.2024.10.006.","journal-title":"Clin Breast Cancer"},{"key":"1261_CR26","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2023.1634","volume":"17","author":"FE Petracci","year":"2023","unstructured":"Petracci FE, Villarreal-Garza C, Arga\u00f1araz F, Abuin GG, Pe\u00f1aloza J, Flores MA, et al. LuciA-15\u2014a real-world prospective study of PARP inhibitors for the treatment of patients with HER-2 negative metastatic breast cancer with germline and\/or somatic mutation of BRCA genes or homologous recombination repair related genes. Ecancermedicalscience. 2023;17:1634. https:\/\/doi.org\/10.3332\/ecancer.2023.1634.","journal-title":"Ecancermedicalscience"},{"key":"1261_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00947-8","volume":"12","author":"M H\u00f6rner","year":"2026","unstructured":"H\u00f6rner M, Hartkopf A, John N, Ziegler P, H\u00e4berle L, Uhrig S, et al. PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-results from the prospective PRAEGNANT registry. NPJ Breast Cancer. 2026;12:60. https:\/\/doi.org\/10.1038\/s41523-026-00947-8.","journal-title":"NPJ Breast Cancer"},{"key":"1261_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1734049","author":"G Zheng","year":"2022","unstructured":"Zheng G, Leone JP. Male breast cancer: an updated review of epidemiology, clinicopathology, and treatment. J Oncol. 2022. https:\/\/doi.org\/10.1155\/2022\/1734049.","journal-title":"J Oncol"},{"key":"1261_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00814","volume":"9","author":"S Yadav","year":"2025","unstructured":"Yadav S, Couch FJ, Hillman S, Luo L, Li W, Li Q, et al. Real-world germline BRCA testing, poly(ADP-ribose) polymerase inhibitor utilization, and survival outcomes in human epidermal growth factor receptor 2-negative metastatic breast cancer. JCO Precis Oncol. 2025;9:e2400814. https:\/\/doi.org\/10.1200\/PO-24-00814.","journal-title":"JCO Precis Oncol"},{"key":"1261_CR30","doi-asserted-by":"publisher","first-page":"P2-10-17","DOI":"10.1158\/1557-3265.SABCS24-P2-10-17","volume":"31","author":"P Razavi","year":"2025","unstructured":"Razavi P, et al. A randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4\/6i plus physician\u2019s choice endocrine therapy or + camizestrant in patients w\/ BRCA1\/BRCA2\/PALB2 mutations & HR+\/HER2\u2212 advanced breast cancer (EvoPAR-Breast01). Clin Cancer Res. 2025;31:P2-10\u20137.","journal-title":"Clin Cancer Res"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01261-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:33:04Z","timestamp":1792632784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01261-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":30,"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01261-w","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zeynep S\u0131la G\u00f6kdere, Taha Koray \u015eahin, \u0130rem Bilgetekin, Naziyet K\u00f6se Baytemur, Mustafa Seyyar, Melike Yaz\u0131c\u0131, Ercan G\u00fcm\u00fc\u015fburun, Seval Akay, Damla G\u00fcnen\u00e7, \u00c7a\u011fla Karao\u011flu, P\u0131nar Ezgi Dama, Ece \u015eahin Haf\u0131zo\u011flu, Serkan Menek\u015fe, Berkan Karadurmu\u015f, Talha \u00d6z\u00fcdo\u011fru, Galip Can Uyar, G\u00f6rkem Turhan, Bahad\u0131r K\u00f6yl\u00fc, Ferit Turan, Ay\u015fe Nuransoy Cengiz, Ali Kaan G\u00fcren, Osman B\u00fct\u00fcn, Cevher Burcu Salman, Asl\u0131 Ge\u00e7gel, \u015e\u00fcheda Ata\u015f \u0130pek, Esra Asarkaya, Bedriye A\u00e7\u0131kg\u00f6z Y\u0131ld\u0131z, Ahmet \u00dcnl\u00fc, Elif \u015eahin, Ekin Aky\u0131ld\u0131z Usta, H\u00fcseyin Kanmaz, Ece Esin, Engin Erdemo\u011flu, Atilla Y\u0131ld\u0131r\u0131m, Musa Bar\u0131\u015f Aykan, T\u00fclay Ku\u015f, Mustafa \u015eahbazlar, Erdem \u00c7ubuk\u00e7u, H\u00fcseyin Salih Semiz, Fatih Sel\u00e7ukbiricik, Mevl\u00fcde \u0130nan\u00e7, Murat Sar\u0131, B\u00fclent Karabulut, Hatice Odaba\u015f, Ertu\u011frul Bayram, Gamze G\u00f6k\u00f6z Do\u011fu, Banu \u00d6zt\u00fcrk, Zeynep G\u00fcls\u00fcm G\u00fc\u00e7, Ulus Ali \u015eanl\u0131, Burcu \u00c7akar, Erhan G\u00f6kmen, Berna \u00c7akmak \u00d6ks\u00fczo\u011flu, Devrim \u00c7abuk, Sercan Aksoy, and Hasan \u00c7a\u011fr\u0131 Y\u0131ld\u0131r\u0131m declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Clinical Research Ethics Committee of Ege University Faculty of Medicine, Izmir, T\u00fcrkiye (approval date: 20 November 2025; approval no.: 25-11.1-T\/65).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the ethics committee due to the study\u2019s retrospective design and the use of anonymized patient data.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are not publicly available due to privacy reasons, but are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","label":"Data Availability Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: Z.S.G. and H.\u00c7.Y.; methodology: Z.S.G., A.G. and H.\u00c7.Y.; software: Z.S.G.; validation: Z.S.G.; formal analysis, Z.S.G. and H.\u00c7.Y.; investigation: A.G., M.S., and H.\u00c7.Y.; resources: Z.S.G.; data curation: Z.S.G., T.K.\u015e., \u0130.B., E.G., A.K.G., E.A.U., P.E.D., M.S., T.\u00d6.,M.Y., O.B., U.A.\u015e., A.G., P.E.D., H.K., B.K., A.N.C., and H.\u00c7.Y.; writing\u2014original draft preparation: A.K.G.; writing\u2014review and editing: Z.S.G. A.G., D.G., and H.\u00c7.Y.; visualization: Z.S.G.; supervision: Z.S.G. and H.\u00c7.Y.; project administration: Z.S.G. and H.\u00c7.Y. All authors have read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}